, Volume 10, Issue 1, pp 4-10
Date: 17 Dec 2010

HCV Response-Guided Therapy: Should Treatment Length Be Shortened or Extended?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The treatment of chronic HCV has traditionally been for a fixed duration based on genotype. We now recognize that patients respond to treatment along different time lines. This appears to be secondary to various clinical, histologic, and genetic host factors. The time that it requires for a patient to become HCV RNA undetectable after initiating treatment is now recognized as one of the most important determinants of sustained virologic response. This information can be used to adjust the duration of peginterferon and ribavirin, either shorter or longer, and allows therapy to be tailored to the specific needs of each patient. This concept is referred to as response-guided therapy.